Kosick, Heather Mary-Kathleen http://orcid.org/0000-0001-9163-9448
Keyrouz, Aline
Adeyi, Oyedele
Sebastiani, Giada
Patel, Keyur
Funding for this research was provided by:
Gilead Sciences (27127, 267806)
Department of Medicine, McGill University
Article History
Received: 18 June 2020
Accepted: 24 November 2020
First Online: 3 January 2021
Compliance with Ethical Standards
:
: GS has acted as speaker for Merck, Gilead, Abbvie, Novonordisk, Novartis, served as an advisory board member for Merck, Novartis, Gilead and Intercept, and has received unrestricted research funding from Merck and Theratechnologies Inc. KP has the following declarations: (1) Gilead-Advisory Board, consulting, research grants; (2) Novartis-Advisory Board; (3) Intercept-Advisory Board.
: This study was performed according to the protocol and guidelines of Good Clinical Practice/ICH, based upon the principles outlined in the Declaration of Helsinki and local and national guidelines governing the conduct of clinical research studies. All patient data used for the purpose of this retrospective study were de-identified and anonymized, and patient consent was not required. This study was approved by the Institutional Research Ethics Board at both the University Health Network and the McGill University Health Centre.